PMID- 30654809
OWN - NLM
STAT- MEDLINE
DCOM- 20190429
LR  - 20211204
IS  - 1743-422X (Electronic)
IS  - 1743-422X (Linking)
VI  - 16
IP  - 1
DP  - 2019 Jan 17
TI  - Effectiveness of ombitasvir/paritaprevir/ritonavir, dasabuvir for HCV in HIV/HCV 
      coinfected subjects: a comprehensive analysis.
PG  - 11
LID - 10.1186/s12985-018-1114-4 [doi]
LID - 11
AB  - BACKGROUND: Data on the treatment of patients with hepatitis C virus (HCV)/human 
      immunodeficiency virus (HIV) coinfection remains limited. A comprehensive 
      analysis was performed to evaluate the efficacy and safety of ombitasvir 
      (OBV)/paritaprevir (PTV)/ritonavir(r) +/- dasabuvir (DSV) +/- ribavirin (RBV) for 
      treatment in HCV/HIV coinfected patients. METHODS: We systematically searched and 
      included studies that enrolled patients with HIV/HCV coinfection using the 
      OBV/PTV/r +/- DSV +/- RBV regimens and reported sustained virological response after 
      12 weeks (SVR12) end-of-treatment. Heterogeneity of results was assessed and 
      pooled SVR rates were computed with 95% confidence intervals (95%CI). Subgroup 
      analysis and assessment of publication bias through Egger's test were further 
      performed. RESULTS: Ten studies containing 1358 coinfected patients were included 
      in this study. The pooled estimate of SVR12 was 96.3% (95%CI: 95.1-97.4). 
      Subgroup analysis showed that pooled SVR12 rate was 96.2% (95% CI: 94.8-97.4) for 
      patients with genotype (GT) 1 and 98.8% (95% CI: 95.1-100.0) for those with GT4. 
      The SVR12 rates for the treatment-naive (TN) and treatment-experienced (TE) 
      patients were 96.8% (95% CI, 94.8-98.5) and 98.9% (95% CI, 96.4-100.0), 
      respectively. Pooled SVR12 rate was 97.8(95%CI: 94.6-99.8) for patients with 
      cirrhosis and 96.7% (95%CI: 95.3-97.8) without cirrhosis. The pooled incidence of 
      any adverse events (AEs) and serious adverse events (SAEs) was 73.9% (95%CI: 
      38.1-97.6) and 2.7% (95%CI: 0.0-9.5). Publication bias did not exist in this 
      study. CONCLUSIONS: The comprehensive analysis showed high efficacy for the 
      OBV/PTV/r +/- DSV +/- RBV regimen in patients coinfected with HIV and HCV, regardless 
      of genotypes, history of treatment and the presence or absence of cirrhosis.
FAU - Wu, Jingjing
AU  - Wu J
AD  - Department of Epidemiology and Biostatistics, School of Public Health, Nanjing 
      Medical University, Nanjing, 211166, China.
FAU - Huang, Peng
AU  - Huang P
AD  - Department of Epidemiology and Biostatistics, School of Public Health, Nanjing 
      Medical University, Nanjing, 211166, China.
AD  - Key Laboratory of Infectious Diseases, School of Public Health, Nanjing Medical 
      University, Nanjing, 211166, China.
AD  - Institute of Epidemiology and Microbiology, Huadong Research Institute for 
      Medicine and Biotechnics, Nanjing, 210002, China.
FAU - Fan, Haozhi
AU  - Fan H
AD  - Department of Epidemiology and Biostatistics, School of Public Health, Nanjing 
      Medical University, Nanjing, 211166, China.
FAU - Tian, Ting
AU  - Tian T
AD  - Department of Epidemiology and Biostatistics, School of Public Health, Nanjing 
      Medical University, Nanjing, 211166, China.
FAU - Xia, Xueshan
AU  - Xia X
AD  - Faculty of Life Science and Technology, Kunming University of Science and 
      Technology, Yunnan, 650550, China.
FAU - Fu, Zuqiang
AU  - Fu Z
AD  - Department of Epidemiology and Biostatistics, School of Public Health, Nanjing 
      Medical University, Nanjing, 211166, China.
FAU - Wang, Yan
AU  - Wang Y
AD  - Department of Epidemiology and Biostatistics, School of Public Health, Nanjing 
      Medical University, Nanjing, 211166, China.
FAU - Ye, Xiangyu
AU  - Ye X
AD  - Department of Epidemiology and Biostatistics, School of Public Health, Nanjing 
      Medical University, Nanjing, 211166, China.
FAU - Yue, Ming
AU  - Yue M
AD  - Department of Infectious Diseases, The First Affiliated Hospital of Nanjing 
      Medical University, Nanjing, 210029, China. njym08@163.com.
FAU - Zhang, Yun
AU  - Zhang Y
AD  - Department of Epidemiology and Biostatistics, School of Public Health, Nanjing 
      Medical University, Nanjing, 211166, China. zhangyunvip@126.com.
AD  - Key Laboratory of Infectious Diseases, School of Public Health, Nanjing Medical 
      University, Nanjing, 211166, China. zhangyunvip@126.com.
AD  - Institute of Epidemiology and Microbiology, Huadong Research Institute for 
      Medicine and Biotechnics, Nanjing, 210002, China. zhangyunvip@126.com.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20190117
PL  - England
TA  - Virol J
JT  - Virology journal
JID - 101231645
RN  - 0 (Anilides)
RN  - 0 (Antiviral Agents)
RN  - 0 (Carbamates)
RN  - 0 (Cyclopropanes)
RN  - 0 (Lactams, Macrocyclic)
RN  - 0 (Macrocyclic Compounds)
RN  - 0 (Sulfonamides)
RN  - 2302768XJ8 (ombitasvir)
RN  - 56HH86ZVCT (Uracil)
RN  - 9DLQ4CIU6V (Proline)
RN  - CKR7XL41N4 (2-Naphthylamine)
RN  - DE54EQW8T1 (dasabuvir)
RN  - HG18B9YRS7 (Valine)
RN  - O3J8G9O825 (Ritonavir)
RN  - OU2YM37K86 (paritaprevir)
SB  - IM
MH  - 2-Naphthylamine
MH  - Adult
MH  - Anilides/*therapeutic use
MH  - Antiviral Agents/*therapeutic use
MH  - Carbamates/*therapeutic use
MH  - Clinical Trials as Topic
MH  - Coinfection/*drug therapy/virology
MH  - Cyclopropanes
MH  - Drug Therapy, Combination
MH  - Female
MH  - HIV
MH  - HIV Infections/virology
MH  - Hepacivirus/drug effects/genetics
MH  - Hepatitis C, Chronic/*drug therapy
MH  - Humans
MH  - Lactams, Macrocyclic
MH  - Macrocyclic Compounds/*therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Observational Studies as Topic
MH  - Proline/analogs & derivatives
MH  - Ritonavir/*therapeutic use
MH  - Sulfonamides/*therapeutic use
MH  - Sustained Virologic Response
MH  - Uracil/*analogs & derivatives/therapeutic use
MH  - Valine
PMC - PMC6337763
OTO - NOTNLM
OT  - 3DAA
OT  - HCV
OT  - HIV
OT  - SVR12
COIS- ETHICS APPROVAL AND CONSENT TO PARTICIPATE: Not applicable. CONSENT FOR 
      PUBLICATION: Not applicable. COMPETING INTERESTS: The authors declare that they 
      have no competing interests. PUBLISHER'S NOTE: Springer Nature remains neutral 
      with regard to jurisdictional claims in published maps and institutional 
      affiliations.
EDAT- 2019/01/19 06:00
MHDA- 2019/04/30 06:00
PMCR- 2019/01/17
CRDT- 2019/01/19 06:00
PHST- 2018/08/19 00:00 [received]
PHST- 2018/12/27 00:00 [accepted]
PHST- 2019/01/19 06:00 [entrez]
PHST- 2019/01/19 06:00 [pubmed]
PHST- 2019/04/30 06:00 [medline]
PHST- 2019/01/17 00:00 [pmc-release]
AID - 10.1186/s12985-018-1114-4 [pii]
AID - 1114 [pii]
AID - 10.1186/s12985-018-1114-4 [doi]
PST - epublish
SO  - Virol J. 2019 Jan 17;16(1):11. doi: 10.1186/s12985-018-1114-4.